Conference Track

Clinical Complications of HIV and Its Therapy

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

NRTI Use Associated With Inaccurate HbA1c Glucose Level Tests in HIV-Positive Diabetic Patients
Tenofovir Use Does Not Affect Insulin Sensitivity and Reduces Total and LDL Cholesterol in Healthy Volunteers
NFHL Cohort: Prolonged QT Interval Associated With Atherosclerosis Markers in HIV-Infected Patients
Coronary Plaque Volume Correlates With Antiretroviral Therapy Duration in HIV Patients
High Incidence of Pulmonary Arterial Hypertension Identified in Treated, Asymptomatic HIV-Infected Patients at Low Risk for AIDS or Cardiovascular Disease
SMART: Continuous Antiretroviral Therapy Associated With Greater Loss of Bone Mineral Density Than Intermittent Therapy
No Difference in Renal Function With Tenofovir vs Other NRTIs in Initial Antiretroviral Regimens in Hopkins Cohort
No Association Between Tenofovir and Renal Function Decline Over 2 Years, Regardless of Concomitant PI vs NNRTI, in Single-Center Patient Cohort
Normal Free Testosterone Levels Found Protective of Bone Mineral Density in HIV-Infected Men
Ritonavir Dose Does Not Significantly Affect Limb, Trunk Fat, or Bone Mineral Density in Therapy-Naive Patients Treated for 96 Weeks With Fosamprenavir/Ritonavir
VACS: Diabetes Risk Not Increased by HIV Infection in Large Cohort Comparison Study With Age-Matched, Uninfected Controls

Expert Analysis

Clinical Complications of HIV and Its Therapy

Faculty:

Judith S. Currier, MD, MSc
Donald P. Kotler, MD
William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the relationship, if any, between antiretroviral agents and renal function in HIV-infected patients
Describe data that inform on the effects of antiretroviral therapy on bone mineral density in HIV-infected patients
Explain data on risk of hepatotoxicity in virologically suppressed patients switching therapy to nevirapine
Recount data on the incidence of diabetes in HIV-infected vs the uninfected population

CME CREDIT INFORMATION

Release Date: 12/11/08

Expiration Date: 12/10/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.